James Chen, founder and Chairman of the board of Vetco, the first Taiwan-based veterinary company to have successfully developed an innovative veterinary oncology product, documents the main specificities of Vetco’s flagship product, Antican®, as well as his strategy to bring this ground-breaking treatment onto the most advanced animal health markets in the world, namely the US and Europe.
How would you assess the potential of the veterinary market for oncology products?
"The market for anti-cancer treatments for animals, particularly companion animals like dogs and cats, has huge potential and is at this point really an undeveloped, blue ocean market."
